CLAIMS:

1. Use of PF-07220060 in the manufacture of a medicament for the treatment of cancer in a subject in need thereof which the medicament is to be administered in a therapeutically effective unit dosage of PF-07220060 in the amount of from 100 mg ± 10% to 500 mg ± 10% twice per day BID.

2. The use of claim 1, wherein the therapeutically effective amount is from 300 mg ± 10% to 500 mg ± 10% BID.

3. The use of claim 1 or 2, wherein the therapeutically effective amount is 300 mg ± 10% BID.

4. The use of claim 1 or 2, wherein the therapeutically effective amount is 400 mg ± 10% BID.

5. The use of any one of claims 1 to 4, wherein PF-07220060 is to be administered continuously.

6. The use of any one of claims 1 to 5, wherein PF-07220060 is to be administered in a tablet or capsule form.

7. Use of PF-07220060 and an endocrine therapy agent in the manufacture of a medicament for the treatment of cancer in a subject in need thereof which the medicament is to be administered in a therapeutically effective unit dosage of PF-07220060 in the amount of from 100 mg ± 10% to 500 mg ± 10% BID.

8. The use of claim 7, wherein the endocrine therapy agent is an aromatase inhibitor, an androgen receptor inhibitor, a selective estrogen receptor degrader (SERD), or a selective estrogen receptor modulator (SERM).

9. The use of claim 7, wherein the endocrine therapy agent is selected from the group consisting of letrozole, anastrozole, exemestane, fulvestrant, elacestrant,

amcenestrant, giredestrant, camizestrant, AZD9496, rintodestrant, ZN-c5, LSZ102, LY3484356, SHR9549, tamoxifen, raloxifene, toremifene, lasofoxifene, bazedoxifene and afimoxifene.

10. The use of claim 7, wherein the endocrine therapy agent is letrozole or fulvestrant.

11. The use of any one of claims 7-10, wherein the subject is to be administered the endocrine therapy agent and subsequently to be administered PF-07220060.

12. The use of claim 1 or 7, wherein the subject has been previously treated with chemotherapy, radiotherapy, and/or surgical resection.

13. The use of claim 1 or 7, wherein the subject has been previously treated with a CDK4/6 inhibitor.

14. The use of claim 1 or 7, wherein the subject has been previously treated with an endocrine therapy agent.

15. The use of claim 1 or 13, wherein the subject is a mammal.

16. The use of any one of claims 1 to 15, wherein the subject is suffering from breast cancer, ovarian cancer, fallopian tube cancer, primary peritoneal cancer, bladder cancer, uterine cancer, prostate cancer, lung cancer, esophageal cancer, head and neck cancer, colorectal cancer, kidney cancer, liver cancer, pancreatic cancer, stomach cancer, and thyroid cancer.

17. The use of any one of claims 1 to 16, wherein the cancer is breast cancer selected from any one or more of: hormone receptor positive (HR+), hormone receptor negative (HR-), human epidermal growth factor receptor 2 negative (HER2-), human epidermal growth factor receptor 2 positive (HER2+), HR+/HER2-, ER-/HR+, ER+/HER2-and triple negative breast cancer (TNBC).

18. The use of any one of claims 1 to 16, wherein the cancer is NSCLC, prostate, colorectal cancer, liposarcoma, or tumors characterized by amplification or overexpression of CDK4 and/or CCND1.

19. A medicament comprising a therapeutically effective amount of PF-07220060 for use in treating cancer in a subject in need thereof, wherein the therapeutically effective amount is from 100 mg ± 10% to 500 mg ± 10% BID.

20. A medicament comprising a therapeutically effective amount of PF-07220060 and an endocrine therapy agent for use in treating cancer in a subject in need thereof, wherein the therapeutically effective amount is from 100 mg ± 10% to 500 mg ± 10% BID.